LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR Inc.

In a report released yesterday, from BTIG maintained a Hold rating on LENSAR. The company’s shares closed yesterday at $10.45. Currently, the analy...

BTIG Sticks to Its Hold Rating for LENSAR (LNSR)

Lake Street analyst Frank Takkinen reiterated a Hold rating on LENSAR today and set a price target of $15.00. Takkinen covers the Healthcare sector...

Current Quarter	$NA	Next Quarter	$NA
Current Year	$NA	Next Year	$NA
QoQ Growth	NaN%	YoY Growth	NaN%
3Y EPS CAGR	+0.0%	Target Price	$15.00
Consensus	Buy	Upside	+52.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LNSR	$9.83	+1.34%	32.16K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LNSR	$9.83	+1.3%	32.16K
3
4
5
6

LNSR

LNSR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get LENSAR Inc. Data in Excel

Get LENSAR Inc. Data in Excel